HomeCompareSNPHF vs PEP

SNPHF vs PEP: Dividend Comparison 2026

SNPHF yields 2.31% · PEP yields 3.63%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 PEP wins by $93.7K in total portfolio value· pulled ahead in Year 4
10 years
SNPHF
SNPHF
● Live price
2.31%
Share price
$10.99
Annual div
$0.25
5Y div CAGR
33.6%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$48.2K
Annual income
$8,450.71
Full SNPHF calculator →
PEP
PepsiCo Inc.
● Live price
3.63%
Share price
$156.82
Annual div
$5.69
5Y div CAGR
40.4%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$141.9K
Annual income
$61,875.67
Full PEP calculator →

Portfolio growth — SNPHF vs PEP

📍 PEP pulled ahead of the other in Year 4

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodSNPHFPEP
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, SNPHF + PEP cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
SNPHF pays
PEP pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

SNPHF
Annual income on $10K today (after 15% tax)
$196.32/yr
After 10yr DRIP, annual income (after tax)
$7,183.10/yr
PEP
Annual income on $10K today (after 15% tax)
$308.41/yr
After 10yr DRIP, annual income (after tax)
$52,594.32/yr
At 15% tax rate, PEP beats the other by $45,411.22/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of SNPHF + PEP for your $10,000?

SNPHF: 50%PEP: 50%
100% PEP50/50100% SNPHF
Portfolio after 10yr
$95.1K
Annual income
$35,163.19/yr
Blended yield
36.99%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on PEP right now

SNPHF
No analyst data
PEP
Analyst Ratings
1
Strong
15
Buy
27
Hold
1
Sell
Consensus: Hold
Price Target
$172.43
+10.0% upside vs current
Range: $156.00 — $191.00
Altman Z
3.6
Piotroski
7/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

SNPHF buys
0
PEP buys
0
No recent congressional trades found for SNPHF or PEP in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricSNPHFPEP
Forward yield2.31%3.63%
Annual dividend / share$0.25$5.69
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR33.6%40.4%
Portfolio after 10y$48.2K$141.9K
Annual income after 10y$8,450.71$61,875.67
Total dividends collected$24.8K$123.0K
Payment frequencyquarterlyquarterly
SectorStockConsumer Staples

Year-by-year: SNPHF vs PEP ($10,000, DRIP)

YearSNPHF PortfolioSNPHF Income/yrPEP PortfolioPEP Income/yrGap
1$11,009$308.57$10,849$509.42+$160.00SNPHF
2$12,203$424.14$11,969$750.47+$234.00SNPHF
3$13,645$587.05$13,500$1,124.14+$145.00SNPHF
4← crossover$15,419$819.56$15,680$1,721.66$261.00PEP
5$17,655$1,156.39$18,929$2,715.34$1.3KPEP
6$20,544$1,653.23$24,023$4,450.80$3.5KPEP
7$24,384$2,402.01$32,510$7,669.92$8.1KPEP
8$29,651$3,559.74$47,709$14,093.60$18.1KPEP
9$37,131$5,404.68$77,415$28,083.48$40.3KPEP
10$48,181$8,450.71$141,922$61,875.67$93.7KPEP

SNPHF vs PEP: Complete Analysis 2026

SNPHFStock

Santen Pharmaceutical Co., Ltd. researches and develops, manufactures, and markets pharmaceuticals and medical devices in Japan and internationally. It offers various pharmaceutical products to treat glaucoma and ocular hypertension, such as DE-111, which is in Phase III clinical trial; DE-117 in Japan; DE-126 that is in Phase IIb clinical trial; DE-128 in Europe, as well as is in Phase II/III clinical trial in the United States; and DE-130A that is in Phase III clinical trial. In addition, the company provides DE-114A to treat allergic conjunctivitis; DE-076C for the treatment of vernal keratoconjunctivitis; and DE-109, which is in Phase III clinical trial to treat uveitis. Further, it offers DE-127 to treat myopia, which is in Phase II/III clinical trial in Japan, as well as is in Phase III in Asia; DE-089C, which has completed Phase III clinical trials for the treatment of dry eye; and STN1013400, which is in Phase I clinical trials for the treatment of myopia. Additionally, the company offers over-the-counter pharmaceutical products. The company was formerly known as Santendo Pharmaceutical Co., Ltd. and changed its name to Santen Pharmaceutical Co., Ltd. in 1958. Santen Pharmaceutical Co., Ltd. was founded in 1890 and is headquartered in Osaka, Japan.

Full SNPHF Calculator →

PEPConsumer Staples

PepsiCo, Inc. manufactures, markets, distributes, and sells various beverages and convenient foods worldwide. The company operates through seven segments: Frito-Lay North America; Quaker Foods North America; PepsiCo Beverages North America; Latin America; Europe; Africa, Middle East and South Asia; and Asia Pacific, Australia and New Zealand and China Region. It provides dips, cheese-flavored snacks, and spreads, as well as corn, potato, and tortilla chips; cereals, rice, pasta, mixes and syrups, granola bars, grits, oatmeal, rice cakes, simply granola, and side dishes; beverage concentrates, fountain syrups, and finished goods; ready-to-drink tea, coffee, and juices; dairy products; and sparkling water makers and related products. It serves wholesale and other distributors, foodservice customers, grocery stores, drug stores, convenience stores, discount/dollar stores, mass merchandisers, membership stores, hard discounters, e-commerce retailers and authorized independent bottlers, and others through a network of direct-store-delivery, customer warehouse, and distributor networks, as well as directly to consumers through e-commerce platforms and retailers. The company was founded in 1898 and is headquartered in Purchase, New York.

Full PEP Calculator →
📬

Get this SNPHF vs PEP comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

SNPHF vs SCHDSNPHF vs JEPISNPHF vs OSNPHF vs KOSNPHF vs MAINSNPHF vs MOSNPHF vs PMSNPHF vs GIS

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.